Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.
Patients whose immune systems had specific activated cell types before immunotherapy for head-and-neck cancer showed better tumor shrinkage, pointing toward predictive biomarkers.
BACKGROUND: Neoadjuvant immunotherapy has emerged as a promising strategy for patients with head and neck squamous cell carcinoma. Patients who achieved robust pathological regression displayed higher baseline frequencies of activated natural killer T cells and exhausted T cells, with further expansion after treatment.
What the study was
- Study design
- Randomized study
- Population
- patients
- Sample size
- 20
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal for immunotherapy of cancer
Why it surfaced
Score 7/10 [PROMISING_PRELIMINARY]: Randomized study (Journal Article) matched 'Novel therapeutics: immunotherapy, CAR-T'. Components — novelty:2/3, relevance:2/3, design:2/2, population:1/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.